India Sector Consolidation Regulatory Filings — March 01, 2026

Composite Scheme of Arrangement effective March 1, 2026 per E-Form INC-28 and NCLT Ahmedabad order Feb 17, high materiality 9/10 enables demerger value unlock

Signed SPA March 1, 2026 for 100% acquisition of Trilogy UK (revenue +26% YoY to GBP 2.34M from 1.86M), arm's length cash deal at GBP 702K

Wholly owned sub Indegene Healthcare UK acquiring two London-based healthcare providers, strategic consolidation in services

Incorporated GKREL Feb 28, 2026 as step-down WOS with ₹5L capital for Karnataka renewables generation/transmission

Compliance with Sections 230-232 Companies Act and SEBI Reg 30, scheme clauses 1.9/20 met, neutral sentiment with no disruptions

Trilogy UK revenue growth 26% YoY outperforms DT UK's -31% decline, selective acquisition targets high-performers (avg target rev GBP 4.37M)

100% stake in new GKREL via 50K shares @ ₹10, no govt approvals/cash outlay needed, positive sentiment materiality 4/10

Expected completion by March 31, 2026 for both UK deals, internal restructuring classified boosts healthcare sector footprint

Demerger from Adicon Ceramica Tiles Pvt to two resulting cos, follows prior disclosure Feb 20, establishes clear effective date

Strategic expansion outside core business into renewables, newly incorporated sub yet to commence but positions for growth

Targets incorporated 2011/2013 with established ops (DT FY25 rev GBP 6.4M), cash deals signal strong liquidity

High materiality 9/10 vs GMR 4/10, NCLT petition C.P.(CAA)/48(AHM)2025 outperforms in regulatory progress

DT UK revenue -31% YoY (GBP 9.24M to 6.41M), acquisition of underperforming target at GBP 2M raises integration/turnaround risks

Divergent target trends (Trilogy +26% vs DT -31% YoY) yield mixed sentiment 8/10 materiality, potential dilution of growth

Post-effective date March 1 ops from demerger unproven, neutral sentiment may mask execution hurdles under Section 232(5)

Completion targeted March 31, 2026 but UK-based targets introduce forex/regulatory delays for Indian parent

GKREL newly incorporated Feb 28, no prior turnover/ops, renewables dev outside core business exposes to project delays

DT UK acquired GBP 2M despite -31% YoY rev decline (vs Trilogy GBP 0.7M at +26%), overpay risk on distressed asset

Relies on NCLT order Feb 17 conditions precedent (clause 20), any non-compliance post-filing could unwind scheme

2/3 filings via wholly owned subs signal heavy parent reliance, no diversification in deal structures

Effective scheme Mar 1, 2026 demerges Adicon Ceramica to Asian Granito/Adicon Ceramics, potential tiles segment re-rating

Acquire Trilogy UK (+26% YoY rev) for GBP 702K, consolidates UK services footprint for Indegene's global expansion

GKREL for Karnataka RE plant dev, taps high-growth sector with zero cash outlay via equity sub

Targets avg rev GBP 4.37M, Trilogy outperformance vs DT signals bargain hunting in healthcare services

9/10 score vs peers, NCLT-approved scheme positions as tiles consolidation leader post-demerger

Arm's length cash deals GBP 2.7M total, efficient capital alloc for internal restructuring without debt

100% control in GKREL, early mover in Karnataka renewables transmission amid India green push

March 31, 2026 close adds GBP 8.74M combined FY25 rev, alpha from post-deal synergies

3 filings on/near Mar 1, 2026 (2 high materiality 8-9/10), signals wave of deals via demergers/acquisitions/subs for market share gains

Indegene targets show +26%/-31% YoY rev divergence (avg -2.5%), highlights opportunistic buys in healthcare despite volatility

3/3 use WOS/step-down subs (Indegene UK, GMR GEL-GKREL), low-capital (₹5L/GPB 2.7M) path to control minimizes dilution

Indegene's UK acquisitions (England/Wales, London) contrast domestic Asian Granito/GMR, avg target age 12+ years adds maturity

Positive (GMR)/neutral (Asian)/mixed (Indegene), no bearish flags; renewables/healthcare lead consolidation narratives

NCLT/SEBI compliance (Reg 30, Sections 230-232) across filings, fast-tracks (e.g., Asian effective 2 weeks post-order) aid deal velocity

Monitor SPA closing for DT/Trilogy UK by March 31, 2026 for revenue integration and forex impacts

Track operational metrics and financials post-Mar 1 effective date for Adicon Ceramica value transfer

Watch renewables project approvals and business start post-Feb 28 incorporation

QoQ revenue trends post-acquisition, given FY25 -31% YoY decline, for synergy realization

Any scheme amendments or C.P.(CAA)/48(AHM)2025 updates via Reg 30 disclosures

Governmental nods for Karnataka power plant dev/transmission, despite none required initially

Earnings call or update on +26% YoY growth integration into Indegene healthcare platform